New Hepatitis B Drug Achieves Functional Cure in One in Five Patients

Breakthrough Results Offer Hope for Millions

For the first time in medical history, researchers have demonstrated that a functional cure for chronic hepatitis B is achievable in a significant portion of patients. Two phase III clinical trials involving 1,838 adults across 29 countries showed that approximately one in five participants achieved what researchers call a "functional cure" when treated with the experimental drug bepirovirsen, meaning their immune systems kept the virus under control without medication for more than six months.

This represents a dramatic improvement over current standard treatments, which achieve functional cure rates in only about 3 percent of patients after eight to 10 years of therapy. The breakthrough occurred when patients received weekly injections of bepirovirsen for 24 weeks alongside their regular antiviral pills, with 20% maintaining undetectable virus levels for six months after stopping all treatment—something no patients in the placebo groups achieved.

A Global Health Crisis Demanding Solutions

Chronic hepatitis B affects some 240 million people worldwide and kills approximately 1 million people each year. In highly endemic areas, the virus spreads most commonly from mother to child at birth or through horizontal transmission among young children. The burden is heaviest in the WHO Western Pacific and African regions, with 97 million and 65 million people chronically infected respectively, followed by 61 million in South-East Asia.

Current treatments require lifelong daily medication that merely suppresses the virus rather than eliminating it. The new drug works differently by binding to the virus's genetic components, suppressing viral replication and a key surface protein while stimulating the immune system. Patients who entered the study with the lowest levels of viral surface antigen achieved even higher functional cure rates at 26 percent.

Regulatory Approval and Safety Profile

Bepirovirsen is currently under fast-track review by the U.S. Food and Drug Administration, with a decision expected by October 26. Regulatory authorities in Japan, China, and Europe are also reviewing the drug. The treatment showed manageable side effects, though 16% of patients experienced grade 3 or higher adverse events compared to 3% in the placebo group, with the most common serious side effect being elevated liver enzymes in 6% of patients.

Dr. Anna Lok, a hepatitis expert at the University of Michigan who wasn't involved in the research, called the findings "a major step" but cautioned that more study is needed to determine how long the remission-like state lasts. Researchers emphasized that functional cure eliminates the need for further antiviral treatment, removing risks of drug resistance, non-adherence, costs, and side effects of long-term therapy.

Transforming Treatment Landscape

The development represents the first anti-hepatitis B therapy to complete global phase 3 trials with functional cure as the primary outcome. While experts call the results encouraging, questions remain about affordability and accessibility for patients in resource-poor regions where the disease burden is highest. Industry analysts suggest bepirovirsen may become a blockbuster treatment but anticipate a gradual launch due to screening and monitoring requirements.

This breakthrough could fundamentally change how medicine approaches hepatitis B, shifting from lifelong management to potential cure. For the quarter-billion people living with chronic hepatitis B worldwide, these results offer the first realistic hope of freedom from a virus that has long been considered incurable.